Lixte Biotechnology Holdings, Inc.
LIXT
$4.20
$0.143.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 145.13% | 16.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 132.50% | 9.61% | |||
| Operating Income | -132.50% | -9.61% | |||
| Income Before Tax | -155.30% | -9.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -155.30% | -9.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -155.30% | -9.32% | |||
| EBIT | -132.50% | -9.61% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -15.43% | 0.70% | |||
| Normalized Basic EPS | -12.57% | 0.67% | |||
| EPS Diluted | -15.43% | 0.70% | |||
| Normalized Diluted EPS | -12.57% | 0.67% | |||
| Average Basic Shares Outstanding | 126.84% | 10.07% | |||
| Average Diluted Shares Outstanding | 126.84% | 10.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||